Lemborexant 2.5 mg + Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant 15 mg + Lemborexant-matched placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Irregular Sleep-Wake Rhythm Disorder
Conditions
Irregular Sleep-Wake Rhythm Disorder
Trial Timeline
Dec 20, 2016 → Apr 17, 2020
NCT ID
NCT03001557About Lemborexant 2.5 mg + Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant 15 mg + Lemborexant-matched placebo
Lemborexant 2.5 mg + Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant 15 mg + Lemborexant-matched placebo is a phase 2 stage product being developed by Eisai for Irregular Sleep-Wake Rhythm Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03001557. Target conditions include Irregular Sleep-Wake Rhythm Disorder.
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03001557 | Phase 2 | Completed |